KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Yu, Evan Y.
Piulats, Josep M.
Gravis, Gwenaelle
Laguerre, Brigitte
Arija, Jose Angel Arranz
Oudard, Stephane
Fong, Peter C. C.
Kolinsky, Michael Paul
Augustin, Marinela
Feyerabend, Susan
Kam, Audrey E.
Gurney, Howard
Tafreshi, Ali
Retz, Margitta
Berry, William R.
Mar, Nataliya
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Catalan Inst Oncol, Barcelona, Spain
[3] CLCC Inst Paoli Calmettes, Paris, France
[4] Ctr Eugene Marquis, Rennes, France
[5] Hosp Gregorio Maranon, Madrid, Spain
[6] Hop Europeen Georges Pompidou, Paris, France
[7] Auckland City Hosp, Auckland, New Zealand
[8] Cross Canc Inst, Edmonton, AB, Canada
[9] Paracelsus Med Univ, Nurnberg, Germany
[10] Studienpraxis Urol, Nurtingen, Germany
[11] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[12] Macquarie Univ Hosp, Sydney, NSW, Australia
[13] Univ Wollongong, Wollongong, NSW, Australia
[14] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[15] Duke Canc Ctr Cary, Cary, NC USA
[16] UCI Hlth, Orange, CA USA
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhofer, Tilman
    Laguerre, Brigitte
    Arranz, Jose A.
    Oudard, Stephane
    Massard, Christophe
    Heinzelbecker, Julia
    Nordquist, Luke T.
    Carles, Joan
    Kolinsky, Michael P.
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Qiu, Ping
    Poehlein, Christian H.
    Schloss, Charles
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2023, 83 (01) : 15 - 26
  • [32] Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
    Petrylak, Daniel Peter
    Shore, Neal D.
    Bennamoun, Mostefa
    Ratta, Raffaele
    Piulats, Josep M.
    Li, Ben
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] KEYNOTE-046: ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC).
    Stein, Mark N.
    Fong, Lawrence
    Tutrone, Ronald F.
    Mega, Anthony E.
    Lobo, Maurice
    Hong, Quan
    Haas, Naomi B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony M.
    Gurney, Howard
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Linch, M.
    Ferrario, C.
    Stoeckle, M.
    Laguerre, B.
    Arija, J. A. Arranz
    Todenhofer, T.
    Fong, P. C.
    Rodriguez, J. M. Piulats
    Berry, W.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1178 - S1178
  • [36] Keynote-199: Updated analysis of Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel
    Goh, Jeffrey C.
    Antonarakis, Emmanuel S.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    Piulats, Josep M.
    de Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Poehlein, Christian H.
    de Bono, Johann S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 48 - 49
  • [37] Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.
    Antonarakis, Emmanuel S.
    Goh, Jeffrey C.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    Piulats, Josep M.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [38] KEYNOTE-365 COHORT C: PEMBROLIZUMAB plus ENZALUTAMIDE IN PATIENTS WITH ABIRATERONE ACETATE-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)-DATA AFTER MINIMUM OF 22 MONTHS OF FOLLOW-UP
    Appleman, Leonard
    Todenhoefer, Tilman
    Berry, William
    Gurney, Howard
    Retz, Margitta
    Conter, Henry
    Laguerre, Brigitte
    Fong, Peter
    Ferrario, Cristiano
    Gravis, Gwenaelle
    Piulats, Josep
    Emmenegger, Urban
    Shore, Neal
    Romano, Emanuela
    Mourey, Loic
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A374 - A374
  • [39] Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
    Yu, Evan Y.
    Joshua, Anthony M.
    Shore, Neal D.
    Kramer, Gero
    Hu, Haixia
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS250 - TPS250
  • [40] Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study
    Antonarakis, E. S.
    Piulats, J. M.
    Gross-Goupil, M.
    Goh, J. C.
    Vaishampayan, U. N.
    De Wit, R.
    Alanko, T. V.
    Fukasawa, S.
    Tabata, K.
    Feyerabend, S.
    Berger, R.
    Ojamaa, K.
    Hoimes, C. J.
    Sezer, A.
    Omlin, A. G.
    Yachnin, J.
    Niu, C.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S651 - S652
12345